EKF Diagnostics is planning to ramp up the production of the US Food and Drug Administration (FDA)-approved PrimeStore MTM device due to an increase in global demand amid Covid-19 pandemic outbreak.
The sample collection device enables safe handling and transport by deactivating viruses, bacteria, fungi and mycobacterium tuberculosis.
It has been designed to rapidly de-activate pathogen and stabilise RNA for up to four weeks with no requirement for cold storage.
The approach is said to reduce the risk of infection while allowing the samples to be tested by a higher number of laboratories.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
EKF has been rapidly increasing the production to meet the demand of one of the key components in PrimeStore MTM, which is manufactured at the company’s site in Boerne, Texas, US.
The company fulfilled the initial purchase orders worth $1m last month.
Currently, EKF anticipates additional orders worth $3m from Longhorn Vaccines and Diagnostics next month.
The company noted that the majority of the orders will be for the core reagent used within the device. It is in the process of doubling its manufacturing capacity for the reagent to fulfil these and anticipated future orders.
EKF also reported a decrease in the sales of its core diabetes and haemoglobin products in recent weeks due to lockdown measures. However, the increased contribution from the Longhorn manufacturing contract is expected to help the company exceed the overall management budgets for the first half of the year.
EKF said in a statement: “The Board also remains confident of exceeding its expectations for the full year. However, the quantum of this positive trading performance will only be known with certainty as the year progresses and further guidance will be provided later in the year.”